Travere Therapeutics
Last updated Jun 10, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
70%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Nephrology
- SGLT2 Inhibitor
Highest priority development: Over-The-Counter Monograph Drug User Fee Program (OMUFA)
Regulatory precedent
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for TRAVERE; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 70%
Active Signals
1
Investigate Priority
0
Opportunity Score
24
Buyer Quality
8 · Mid-Market
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 10, 2026Score 24FDA Accepts Supplement for FILSPARI (SPARSENTAN) by TRAVERE
Nephrology · SGLT2 Inhibitor
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Over-The-Counter Monograph Drug User Fee Program (OMUFA)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Generic Drugs: Questions & AnswersModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — FILSPARI (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — FILSPARI (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Travere Therapeutics right now?
- Which regulatory precedents should Travere Therapeutics monitor in Nephrology and SGLT2 Inhibitor?
- How does Regulatory Milestone for TRAVERE's FILSPARI Enhances Competitive Positioning compare to the nearest competitive programs?
- What signals require immediate investigation for Travere Therapeutics?
- Summarize the strategic implications of recent developments for Travere Therapeutics.
- Where is the greatest uncertainty in Travere Therapeutics's competitive positioning?